Brinker Capital Investments LLC Buys Shares of 3,167 Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Brinker Capital Investments LLC Buys Shares of 3,167 Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Brinker Capital Investments LLC bought a new stake in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 3,167 shares of the company's stock, valued at approximately $238,000.
根據Brinker Capital Investments LLC在第二季度收購了Turning Point Treateutics，Inc.(納斯達克代碼：TPTX-GET Rating)的新股份，該公司在最近提交給美國證券交易委員會的Form 13F文件中稱。該公司購買了3167股該公司股票，價值約23.8萬美元。
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Captrust Financial Advisors lifted its holdings in Turning Point Therapeutics by 176.5% in the first quarter. Captrust Financial Advisors now owns 1,045 shares of the company's stock valued at $28,000 after acquiring an additional 667 shares during the period. US Bancorp DE lifted its holdings in Turning Point Therapeutics by 139.6% in the first quarter. US Bancorp DE now owns 1,143 shares of the company's stock valued at $31,000 after acquiring an additional 666 shares during the period. Point72 Hong Kong Ltd acquired a new position in shares of Turning Point Therapeutics during the 1st quarter worth $96,000. Syquant Capital Sas acquired a new position in shares of Turning Point Therapeutics during the 2nd quarter worth $339,000. Finally, Stonnington Group LLC acquired a new position in shares of Turning Point Therapeutics during the 2nd quarter worth $383,000. Institutional investors and hedge funds own 90.33% of the company's stock.
其他對衝基金和其他機構投資者最近也買賣了該公司的股票。CapTrust Financial Advisors在第一季度將其在Turning Point Treeutics的持股增加了176.5%。CapTrust Financial Advisors在此期間額外購買了667股，現在擁有1,045股該公司股票，價值2.8萬美元。美國Bancorp DE在第一季度增持了Turning Point Treateutics 139.6%的股份。US Bancorp DE現在擁有1143股該公司的股票，價值3.1萬美元，在此期間又購買了666股。Point72 Hong Kong Ltd在第一季度收購了Turning Point Treeutics價值96,000美元的新股票頭寸。Syquant Capital SAS在第二季度收購了Turning Point Treateutics的新股份，價值33.9萬美元。最後，Stonnington Group LLC在第二季度獲得了價值38.3萬美元的Turning Point Treeutics股票的新頭寸。機構投資者和對衝基金持有該公司90.33%的股票。
Turning Point Therapeutics Stock Performance
轉折點治療公司股票表現
Turning Point Therapeutics stock opened at $76.01 on Friday. The stock has a market cap of $3.81 billion, a PE ratio of -11.02 and a beta of -0.18. The stock has a 50-day moving average price of $75.81 and a 200 day moving average price of $59.18. Turning Point Therapeutics, Inc. has a 52 week low of $23.77 and a 52 week high of $82.20.
Turning Point Treateutics的股票週五開盤報76.01美元。該股市值為38.1億美元，市盈率為-11.02，貝塔係數為-0.18。該股的50日移動均線價格為75.81美元，200日移動均線價格為59.18美元。Turning Point Treateutics，Inc.的52周低點為23.77美元，52周高點為82.20美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Several research analysts have recently issued reports on TPTX shares. Guggenheim set a $76.00 price target on Turning Point Therapeutics in a research note on Monday, June 20th. SVB Leerink downgraded Turning Point Therapeutics from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $101.00 to $76.00 in a research note on Monday, June 13th. Nine equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $78.22.
幾位研究分析師最近發佈了關於TPTX股票的報告。古根海姆在6月20日星期一的一份研究報告中為Turning Point治療公司設定了76.00美元的目標價。SVB Leerink在6月13日(星期一)的一份研究報告中將Turning Point Treateutics的評級從“跑贏大盤”下調至“市場表現”，並將該股的目標價從101.00美元下調至76美元。9名股票研究分析師對該股的評級為持有，3名分析師對該股的評級為買入。根據MarketBeat.com的數據，該股目前的普遍評級為持有，平均目標價為78.22美元。
Insider Buying and Selling at Turning Point Therapeutics
轉折點治療公司的內部買入和賣出
In other Turning Point Therapeutics news, CFO Paolo Tombesi sold 1,183 shares of Turning Point Therapeutics stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $74.94, for a total value of $88,654.02. Following the completion of the sale, the chief financial officer now owns 28,700 shares in the company, valued at approximately $2,150,778. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.60% of the stock is owned by company insiders.
在其他Turning Point Treeutics的消息中，首席財務官保羅·湯貝西在一筆日期為7月27日星期三的交易中出售了1,183股Turning Point治療公司的股票。這隻股票的平均售價為74.94美元，總價值為88,654.02美元。出售完成後，首席財務官現在擁有該公司28,700股，價值約2,150,778美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過以下方式獲取這個環節。8.60%的股份由公司內部人士持有。
Turning Point Therapeutics Profile
轉折點治療簡介
(Get Rating)
(獲取評級)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Turning Point治療公司是一家臨牀階段的精確腫瘤學生物製藥公司，致力於設計和開發針對癌症遺傳驅動因素的治療方法。它開發了一系列酪氨酸激酶抑制劑(TKI)，針對TKI-NAI、̈Ve和TKI預治療患者的癌症基因驅動因素。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- 2 Regional Banks With Sector-Beating Price Performance
- MarketBeat: Week in Review 10/3-10/7
- ConAgra Brands Is A Value Pick For Income Investors
- 3 Stocks With Market-Beating Price Performance
- Lucid Motors May Test Investors' Resolve, But Should They Sell?
- 免費獲取StockNews.com關於轉折點治療(TPTX)的研究報告
- 2家地區性銀行的價格表現優於行業
- MarketBeat：回顧一週10/3-10/7
- 康尼格拉品牌是收益投資者的價值選擇
- 3只股價表現優於大盤的股票
- Lucid Motors可能會考驗投資者的決心，但他們應該出售嗎？
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《轉折點治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Turning Point Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。